1887

Abstract

Bedaquiline (BDQ) is a recently approved antibiotic for the treatment of multidrug-resistant tuberculosis, but its potential against slow-growing mycobacteria (SGM) is still unknown. The objective of this study was to determine the activity of BDQ on SGM by assessing their MIC and minimal bactericidal concentration (MBC). The MIC of BDQ against 17 clinical isolates including and species was determined by the resazurin microtitre assay and the MBC by the c.f.u. determination on 7H10 agar plates. BDQ has a bacteriostatic activity on all SGM tested with a MIC range from 0.03 to 0.007 µg ml and surprisingly a good bactericidal activity on the majority of the isolates tested with an MBC of 1–2 µg ml . Based on these preliminary results BDQ seems to be very promising for treatment of diseases caused by SGM.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001025
2019-08-01
2020-01-28
Loading full text...

Full text loading...

References

  1. Tortoli E. Microbiological features and clinical relevance of new species of the genus Mycobacterium. Clin Microbiol Rev 2014;27:727–752 [CrossRef]
    [Google Scholar]
  2. Martiniano SL, Nick JA, Daley CL. Nontuberculous mycobacterial infections in cystic fibrosis. Clin Chest Med 2016;37:83–96 [CrossRef]
    [Google Scholar]
  3. Sommerstein R, Schreiber PW, Diekema DJ, Edmond MB, Hasse B et al. Mycobacterium chimaera outbreak associated with heater-cooler devices: piecing the puzzle together. Infect Control Hosp Epidemiol 2017;38:103–108 [CrossRef]
    [Google Scholar]
  4. Esteban J, García-Pedrazuela M, Muñoz-Egea MC, Alcaide F et al. Current treatment of nontuberculous mycobacteriosis: an update. Expert Opin Pharmacother 2012;13:967–986 [CrossRef]
    [Google Scholar]
  5. Philley JV, DeGroote MA, Honda JR, Chan MM, Kasperbauer S et al. Treatment of non-tuberculous mycobacterial lung disease. Curr Treat Options Infect Dis 2016;8:275–296 [CrossRef]
    [Google Scholar]
  6. Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs J-M et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223–227 [CrossRef]
    [Google Scholar]
  7. Palomino JC, Martin A. TMC207 becomes bedaquiline, a new anti-TB drug. Future Microbiol 2013;8:1071–1080 [CrossRef]
    [Google Scholar]
  8. Huitric E, Verhasselt P, Andries K, Hoffner SE et al. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007;51:4202–4204 [CrossRef]
    [Google Scholar]
  9. Alexander DC, Vasireddy R, Vasireddy S, Philley JV, Brown-Elliott BA et al. Emergence of mmpT5 variants during bedaquiline treatment of Mycobacterium intracellulare lung disease. J Clin Microbiol 2017;55:574–584 [CrossRef]
    [Google Scholar]
  10. Aguilar-Ayala DA, Cnockaert M, André E, Andries K, Gonzalez-Y-Merchand JA et al. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria. J Med Microbiol 2017;66:1140–1143 [CrossRef]
    [Google Scholar]
  11. Palomino JC, Martin A, Camacho M, Guerra H, Swings J et al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002;46:2720–2722 [CrossRef]
    [Google Scholar]
  12. Martin A, Camacho M, Portaels F, Palomino JC et al. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother 2003;47:3616–3619 [CrossRef]
    [Google Scholar]
  13. Dupont C, Viljoen A, Thomas S, Roquet-Banères F, Herrmann JL et al. Bedaquiline inhibits the ATP synthase in Mycobacterium abscessus and is effective in infected zebrafish. Antimicrob Agents Chemother 2017;61:e01225–17 [CrossRef]
    [Google Scholar]
  14. Brown-Elliott BA, Philley JV, Griffith DE, Thakkar F, Wallace RJ et al. In vitro susceptibility testing of bedaquiline against Mycobacterium avium complex. Antimicrob Agents Chemother 2017;61:e01798–16 [CrossRef]
    [Google Scholar]
  15. Pang Y, Zheng H, Tan Y, Song Y, Zhao Y et al. In vitro activity of bedaquiline against nontuberculous mycobacteria in China. Antimicrob Agents Chemother 2017;61:e02627–16 [CrossRef]
    [Google Scholar]
  16. Lounis N, Gevers T, Van den Berg J, Vranckx L, Andries K et al. ATP synthase inhibition of Mycobacterium avium is not bactericidal. Antimicrob Agents Chemother 2009;53:4927–4929 [CrossRef]
    [Google Scholar]
  17. Soni I, De Groote MA, Dasgupta A, Chopra S et al. Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria. J Med Microbiol 2016;65:1–8 [CrossRef]
    [Google Scholar]
  18. Ruth MM, Sangen JJN, Remmers K et al. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. J Antimicrob Chemother 2019
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001025
Loading
/content/journal/jmm/10.1099/jmm.0.001025
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error